Company Overview - Polyrizon Ltd. is a development stage biotech company focused on innovative intranasal hydrogels and has initiated preclinical studies for intranasal Benzodiazepines (BZDs) targeting acute repetitive seizures and status epilepticus [1][4] - The company utilizes its proprietary Trap and Target™ (T&T) platform for the intranasal administration of BZDs, aiming to provide rapid and patient-friendly seizure rescue therapy [4][6] Industry Context - According to the World Health Organization, epilepsy affects approximately 50 million people globally, with many existing therapies failing to adequately control acute repetitive seizures [2] - The global market for acute repetitive seizures was valued at USD 3.15 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2030 [2] Research Collaboration - The preclinical studies will be conducted in collaboration with Professor Fabio Sonvico from the University of Parma, an expert in intranasal and pulmonary drug delivery solutions [3] Advantages of Intranasal Delivery - Intranasal delivery of BZDs offers several advantages over traditional administration routes, including ease of use and increased accessibility, allowing for rapid administration of life-saving medication in out-of-hospital settings [5]

Raanana, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy is a neurolog ...